Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1617 1623 1627
This examiner grants 44% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17760090 | ELONGATION FACTOR 1-ALPHA INHIBITORS AND USES THEREOF | Non-Final OA | The Regents of the University of California |
| 18553840 | DONOR-ACCEPTOR CONJUGATED OLIGOELECTROLYTES FOR CELL LABELLING AND METHODS THEREOF | Non-Final OA | National University of Singapore |
| 18740833 | SMALL MOLECULE TRAIL GENE INDUCTION BY NORMAL AND TUMOR CELLS AS AN ANTICANCER THERAPY | Non-Final OA | The Penn State Research Foundation |
| 17990489 | FLAVONE DERIVATIVES AND USES IN TARGETING CK2-MEDIATED DISEASES AND CONDITIONS | Final Rejection | Salk Institute for Biological Studies |
| 18320173 | NOVEL METHODS | Final Rejection | INTRA-CELLULAR THERAPIES, INC. |
| 18260721 | USP13 INHIBITORS AND METHODS OF USE THEREOF | Non-Final OA | GEORGETOWN UNIVERSITY |
| 17630929 | METHODS OF TREATING POMPE DISEASE | Non-Final OA | Academia Sinica |
| 18038821 | SIRTUIN 6 ACTIVATOR | Final Rejection | KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION |
| 18200148 | Methods for the Prevention and Treatment of Hearing Loss | Final Rejection | Ting Therapeutics, Inc. |
| 18006817 | Products for Treating the JNCL Disease | Final Rejection | University College Cardiff Consultants Limited |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy